IPM Take
This is the uncomfortable side of cure. Hodgkin lymphoma treatment has saved many lives, but long-term survivors can carry elevated risks for decades. Survivorship care cannot be a handout after oncology is finished. It has to be a structured pathway with cardiovascular surveillance, secondary-cancer screening, primary-care coordination and equity monitoring.
Executive Summary
A population-based study in JAMA Network Open examined mortality outcomes among more than 20,000 adults who survived at least five years after Hodgkin lymphoma diagnosis. The study reported 2,899 deaths among survivors compared with 1,481 expected deaths in the general population. Cancer remained a major cause of death, but noncancer causes represented the largest cumulative mortality burden over time, followed by other cancers, cardiovascular disease and Hodgkin lymphoma recurrence. Younger adults and several racial and ethnic minority groups showed particularly elevated relative risks.
Why it matters
- Patients / advocates: Survivors need care plans that do not disappear once treatment ends.
- Clinicians: Cardiovascular disease, second cancers and chronic health risks require long-term surveillance.
- Hospitals / providers: Cancer centres must coordinate with primary care instead of discharging survivorship into uncertainty.
- Public authorities: Cure rates are not enough if preventable late mortality remains unmanaged.
Hodgkin lymphoma is often described as one of oncology’s success stories. It is. But success has an afterlife.
The new JAMA Network Open study makes that clear. Adults who survived at least five years after Hodgkin lymphoma still faced substantially elevated mortality compared with the general population. The excess was not only recurrence. Noncancer causes became a major long-term burden, alongside second cancers and cardiovascular disease.
That should change how systems talk about cure.
The word “cured” can be liberating for patients. It can also become a bureaucratic exit sign. Too many survivors leave intensive oncology care and enter a less organised world where primary care may not know the treatment exposures, cardiology may not be involved early, and screening for late effects depends on the patient’s memory, confidence and access.
That is not survivorship care. That is luck.
Hodgkin lymphoma is a particularly important test case because many patients are diagnosed young. A person cured in their 20s or 30s may live for decades with the long shadow of treatment. Cardiovascular risk, second malignancies, endocrine effects, fatigue and psychosocial consequences can shape the rest of life.
The policy answer is not another survivorship brochure. It is a pathway. Treatment summaries. Risk-stratified follow-up. Cardiovascular screening. Secondary-cancer surveillance. Primary-care handover that actually happens. Digital prompts. Patient navigation. Equity checks for groups carrying higher risk.
The great achievement of Hodgkin lymphoma care is that many patients live. The next achievement should be making sure they are not left to manage the cost of survival alone.
